我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

经心内膜心肌内移植猪自体骨髓间充质干细胞治疗心肌梗死的实验方法 (PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第3期
页码:
320-323
栏目:
基础研究
出版日期:
2012-06-25

文章信息/Info

Title:
Method of catheter-based transendocardial delivery of bone marrow mesenchymal stem cells into swine-infarcted heart
作者:
秦 星1; 武 峰1; 王 晨1; 崔明亮1; 潘 侨1; 刘俊廷2; 曹 丰1
(1.第四军医大学第一附属医院心内科，陕西 西安 710032；2.西安电子科技大学生命科学技术学院生命科学技术研究中心，陕西 西安 710071)
Author(s):
QIN Xing1;  WU Feng1;  WANG Chen1;  CUI Ming-ling1;  PAN Qiao1;  LIU Jun-ting2;  CAO Feng1
(1.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China; 2.Life Sciences and Technology Research Center, School of Life Sciences and Technology, Xidian University, Xi’an 710071 Shaanxi, China)
关键词:
小型猪; 骨髓间充质干细胞; 心肌梗死; 细胞移植
Keywords:
swine;  bone marrow mesenchymal stem cells;  myocardial infarction;  cell transplantation
分类号:
R542.22
DOI:
-
文献标识码:
A
摘要:
目的:探讨经皮经心内膜心肌注射移植猪自体骨髓间充质干细胞(bone marrow mesenchymal stem cells，BMSCs)的治疗心肌梗死(MI)实验方法的可行性和安全性。方法： 选5只雌性健康小型猪通过股动脉入路采用冠脉球囊封堵冠状动脉左前降支60 min建立MI模型。以超声确定MI后两周，采用心肌注射器经心内膜向心肌内注入1×108个小型猪自体红色荧光染料Dil标记的BMSCs，并观察心电图(ECG)的变化。移植BMSCs 8周后，取心肌组织行病理切片，选取含有移植细胞的切片行免疫荧光染色。结果： 4只小型猪成功地建立MI模型（1只因术中室颤死亡）并完成经心内膜的细胞移植，注射过程可出现一过性室性早搏以及短阵室速。通过心肌免疫荧光染色证实，移植的BMSCs已在宿主心肌内存活。结论： 使用心肌注射器经心内膜心肌移植自体BMSCs创伤小，方法可行，具有临床应用的前景。
Abstract:
AIM:To study the feasibility and safety of myocardial syringe for transendocardial delivery of autologous bone marrow mesenchymal stem cell (MSCs) into swine-infarcted hearts. METHODS: The left anterior descending coronary artery of swine was occluded for 60 min by coronary balloon to establish the myocardial infarction model. After 2 weeks, autologous bone marrow MSCs were transplanted into myocardium using myocardial syringe. Eight weeks later, animal hearts were harvested for pathological examination by immunofluorescence. RESULTS: Four swine models were successfully established and one died due to ventricular fibrillation during coronary artery occlusion. Left ventricular contrast imaging localized the endocardium-injected points. Immunofluorescence further demonstrated the survival of the injected cells in the host’s heart. CONCLUSION: Catheter-based transendocardial delivery of bone marrow MSCs into myocardium is feasible and safe.

参考文献/References

[1]Menasche P,Hagege AA,Scorsin M,et al.Myoblast transplantation for heart failure[J].Lancet,2001, 357(9252):279-280.

[2]Stamm C,Westphal B,Kleine HD,et al.Autologous bone-marrow stem-cell transplantation for myocardial regeneration[J].Lancet,2003,361(9351):45-46.

[3]Chen SL,Fang WW,Ye F,et al.Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction[J].Am J Cardiol,2004,94(1):92-95.

[4]Sherman W,Martens TP,Viles-Gonzalez JF,et al.Catheter-based delivery of cells to the heart[J].Nat Clin Pract Cardiovasc Med,2006,3( Suppl 1):S57-S64.

[5]Prockop DJ.Marrow stromal cells as stem cells for nonhematopoietic tissues[J].Science, 1997,276(5309):71-74.

[6]Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cells[J].Science,1999,284(5411):143-147.

[7]Meirelles LS, Fontes AM,Covas DT,et al.Mechanisms involved in the therapeutic properties of mesenchymal stem cells[J]. Cytokine Growth Factor Rev,2009,20(5-6):419-427.

[8]Cheng AS,Yau TM.Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies[J].Semin Thorac Cardiovasc Surg,2008,20(2):94-101.

[9]Tang J,Wang J,Guo L,et al.Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction[J].Mol Cells,2010,29(1):9-19.

[10]Muller-Ehmsen J,Krausgrill B,Burst V,et al.Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction[J].J Mol Cell Cardiol,2006,41(5):876-884.

[11]Doyle B,Kemp BJ,Chareonthaitawee P,et al.Dynamic tracking during intracoronary injection of 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction[J].J Nucl Med,2007,48(10):1708-1714.

[12]Schachinger V,Aicher A,Dobert N,et al.Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium[J].Circulation,2008,118(14):1425-1432.

[13]Hou D,Youssef EA,Brinton TJ,et al.Radiolabeled cell distribution after intramyocardial, intracoronary,and interstitial retrograde coronary venous delivery: implications for current clinical trials[J].Circulation,2005,112(9 Suppl): I150-I156.

[14]Terrovitis J,Lautamaki R,Bonios M,et al.Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery[J].J Am Coll Cardiol,2009,54(17):1619-1626.

[15]Teng CJ, Luo J,Chiu RC,et al.Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty[J].J Thorac Cardiovasc Surg,2006, 132(3):628-632.

备注/Memo

备注/Memo:
收稿日期：2011-11-23.通讯作者：曹丰，教授，主要从事干细胞分子影像研究 Email：fengcao@fmmu.edu.cn 作者简介：秦星，硕士生 Email：bravoqx@gmail.com
更新日期/Last Update: 2012-05-02